Buy & Sell Pinterest Inc (PINS) – Pinterest Inc Price Today
Aura AI Summary
Key Stats
- $10.83BMarket Cap
- MediaSector
- -15.57%3M Drawdown
- $10.73BEnterprise Value
- -Dividend Yield
- 1% Buy | 99% SellTrading Activity
- 75 daysTypical Hold Time
Pinterest Inc (PINS) is currently valued at a market capitalization of $10.83B, with an enterprise value of $10.73B. Over the past 52 weeks, Pinterest Inc has traded between a low of $15.42 and a high of $39.17, highlighting its annual price range. Over the past three months, Pinterest Inc has recorded a drawdown of -15.57%, reflecting recent price volatility. On average, investors hold Pinterest Inc for approximately 75 days, indicating typical investor behavior on the platform.
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Most Recent News
Emerson Electric partners with Aramco to develop advanced corrosion monitoring systems.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...

Modern inflation differs from the 1970s, driven by supply issues, not wage-price spirals.
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...

Atea Pharma shows low drug interaction risk for new Hepatitis C treatment and promising Hepatitis E antiviral data.
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
